

Overcoming drug resistance in lung cancer

~ From single cell to bedside ~

March 18, 2024 (Mon) 17:00 - 19:00

CPD Center, Kanazawa University Hospital 4th floor

Opening remarks : **Seiji Yano** (Kanazawa University)

Chair : **Shigeki Nanjo** (Kanazawa University)

1. Review of drug resistance research.

Trever Bivona

Department of Medicine, Division of Hematology and Oncology,
University of California San Francisco (UCSF)

2. Tissue architectural remodeling of lung adenocarcinoma during EGFR-targeted therapy.

Daniel Lucas Kerr

Department of Medicine, Division of Hematology and Oncology,
University of California San Francisco (UCSF)

3. Antitumor activity of Exarafenib (KIN-2787), a next-generation pan-RAF inhibitor, in BRAF-alteration driven non-small cell lung cancer.

Tadashi Manabe (in person only)

Department of Medicine, Division of Hematology and Oncology,
University of California San Francisco (UCSF)

Hybrid (In person and online: zoom)



Overcoming drug resistance in lung cancer

~ From single cell to bedside ~

March 19, 2024 (Tue) 16:00 - 17:30

**Kanazawa University Nano Life Science Institute 4F
Main Conference Room (Kakuma Campus)**

Chair : Shigeki Nanjo (Kanazawa University)

1. **Overcoming ARID1A mutation induced osimertinib resistance in EGFR-mutant NSCLC leptomeningeal carcinomatosis.**

Koji Fukuda

Division of Medical Oncology, Cancer Research Institute,
Nano Life Science Institute,
Kanazawa University

2. **Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.**

Trever Bivona

Division of Hematology and Oncology,
University of California San Francisco (UCSF)

Closing remarks : Seiji Yano (Kanazawa University)

Hybrid (In person and online: zoom)

